Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1967 : LU65  update : 2022/01/07
CommentHuman lung carcinoma cell line. TKG0442 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Obinata, Masuo
Year of deposit 2004
Original cell TKG0442
Animal human < Mammals
Genus Homo
Species sapiens
Tissue lung
Disease name Lung small cell carcinoma
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0442)
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_1392
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.02% EDTA
Culture information Passage ratio 1 : 4-6 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 3
User's Publication 14


To topTop
Reference
3440  Suzuki K, Miyasaka H, Ota H, Yamakawa Y, Tagawa M, Kuramoto A, Mizuno S.  Purification and partial primary sequence of a chemotactic protein for polymorphonuclear leukocytes derived from human lung giant cell carcinoma LU65C cells.  J Exp Med  1989  169:1895-901  PubMed ID: 2659722   DOI: 10.1084/jem.169.6.1895
2856  Yamada T, Hirohashi S, Shimosato Y, Kodama T, Hayashi S, Ogura T, Gamou S, Shimizu N  Giant cell carcinomas of the lung producing colony-stimulating factor in vitro and in vivo.  Jpn J Cancer Res  1985  76:967-76  PubMed ID: 3935627  
5060  Taya Y, Hosogai K, Hirohashi S, Shimosato Y, Tsuchiya R, Tsuchida N, Fushimi M, Sekiya T, Nishimura S.  A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer.  EMBO J  1984  3(12):2943-6  PubMed ID: 6098458  

To topTop
User's Publication
16498  Nakayama A, Nagashima T, Nishizono Y, Kuramoto K, Mori K, Homboh K, Yuri M, Shimazaki M.  Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models  Br J Cancer  2022  126(5):744-753  PubMed ID: 34795410   DOI: 10.1038/s41416-021-01629-x
20913  Chan CH, Chiou LW, Lee TY, Liu YR, Hsieh TH, Yang CY, Jeng YM.  PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib.  Br J Cancer  2022    PubMed ID: 36319849   DOI: 10.1038/s41416-022-02032-w
12061  Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H.  Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.  Cancer Immunol. Immunother.  2020    PubMed ID: 32086539   DOI: 10.1007/s00262-020-02524-9
13401  Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H.  Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.  Oncoimmunology  2020    PubMed ID: 33457076   DOI: 10.1080/2162402X.2020.1856545
13773  Saigusa D, Motoike IN, Saito S, Zorzi M, Aoki Y, Kitamura H, Suzuki M, Katsuoka F, Ishii H, Kinoshita K, Motohashi H, Yamamoto M.  Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites  Cancer Sci  2020  111(2):667-678  PubMed ID: 31828882   DOI: 10.1111/cas.14278
15895  Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG.  The KRAS G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients  Cancer Discov  2020  10(1):54-71  PubMed ID: 31658955   DOI: 10.1158/2159-8290.CD-19-1167
11609  Hirata-Nozaki Y, Ohkuri T, Ohara K, Kumai T, Nagata M, Harabuchi S, Kosaka A, Nagato T, Ishibashi K, Oikawa K, Aoki N, Ohara M, Harabuchi Y, Uno Y, Takei H, Celis E, Kobayashi H.  PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.  J Transl Med  2019    PubMed ID: 31221178   DOI: 10.1186/s12967-019-1957-5
10606  Kanno E, Kawasaki O, Takahashi K, Takano K, Endo T.  DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.  Exp. Cell Res.  2018  362:111-120  PubMed ID: 29129563   DOI: 10.1016/j.yexcr.2017.11.008
10922  Shigeaki Umeda et al  Loss of IL-24 expression facilitates invasion in lung adenocarcinoma   Int J Clin Exp Pathol  2017  10:173-185   
12943  Okudela K, Mitsui H, Woo T, Arai H, Suzuki T, Matsumura M, Kojima Y, Umeda S, Tateishi Y, Masuda M, Ohashi K.  Alterations in cathepsin L expression in lung cancers  Pathol Int  2016  66(7):386-92  PubMed ID: 27327955   DOI: 10.1111/pin.12424
13988  Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H.  Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy  Oncoimmunology  2016  5(6):e1169356  PubMed ID: 27471649   DOI: 10.1080/2162402X.2016.1169356
7462  Tomita T, Ieguchi K, Sawamura T, Maru Y.  Human serum amyloid A3 (SAA3) protein, expressed as a fusion protein with SAA2, binds the oxidized low density lipoprotein receptor.  PLoS ONE  2015  10:e0118835  PubMed ID: 25738827   DOI: 10.1371/journal.pone.0118835
16553  Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, Kobayashi H.  Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer  J Transl Med  2011  9:191  PubMed ID: 22053850   DOI: 10.1186/1479-5876-9-191
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309   DOI: 10.1111/j.1749-0774.2009.00071.x



Back Back Return Top Page